StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research report sent to investors on Monday morning. The firm issued a sell rating on the stock.
NovaBay Pharmaceuticals Stock Performance
NBY stock opened at $0.08 on Monday. The company’s 50 day moving average price is $0.13 and its 200 day moving average price is $0.22. NovaBay Pharmaceuticals has a fifty-two week low of $0.07 and a fifty-two week high of $1.95. The firm has a market capitalization of $3.03 million, a price-to-earnings ratio of -0.02 and a beta of 1.97.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last released its earnings results on Tuesday, March 26th. The company reported ($0.95) earnings per share for the quarter. The firm had revenue of $3.73 million for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 150.14% and a negative net margin of 65.46%. Equities analysts forecast that NovaBay Pharmaceuticals will post -0.41 EPS for the current fiscal year.
Hedge Funds Weigh In On NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Featured Stories
- Five stocks we like better than NovaBay Pharmaceuticals
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Comprehensive PepsiCo Stock Analysis
- P/E Ratio Calculation: How to Assess Stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bear Market Funds to Watch This Year
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.